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Discussion
Dr JohnHandy (Portland, Ore). Dr Huang, nice job on the pre-
sentation. I thank the association for allowing me to discuss Memo-
rial Sloan–Kettering’s longstanding work in thymic malignancy,
which dates back to the 1980s.
This is a retrospective report of a large series initiated to remedy
the historical mixing of different histologic classifications, study
periods spanning decades, and analytic end points, should it be dis-
ease-free survival or PFS. Therefore Sloan–Kettering has answered
by using the World Health Organization classification. It is a con-
temporary series, and the end point is PFS. The objective was to
define patterns and predictors of disease progression, and it is admi-
rably accomplished in this data-filled article, the manuscript of
which I received far in advance.
I have 3 questions. The high proportion of both TC and thy-
moma that received induction therapy indicated that the diagnosis
was known preoperatively. What exactly is your preoperative
workup? Do you perform biopsies in all patients? Who is getting
PET scans?
Dr Huang. In general, the patients who are receiving induction
therapy have come to us with a diagnosis from the outside, either
with a needle biopsy or tissue obtained through the Chamberlain
procedure. If the patients come to us presenting with a clinical stage
III or IVA tumor, namely with invasion into the mediastinum or
pleural disease, and they do not have biopsy results, we will pro-
ceed with either interventional radiology for a needle biopsy or
do a Chamberlain procedure, if necessary. For any patients in
whom we are considering induction therapy, they will not proceed
to systemic therapy without a biopsy.
In terms of the utility of PET, we prefer to obtain PET scans on
these patients, if possible, looking for distant metastases. This
might be more relevant in the setting of TC. Sometimes these pa-
tients come to us from the outside already having had a PET
scan. If not, we try to obtain one.
Dr Handy. Second, because TC fails distantly regardless of the
completeness of the resection, are you rethinking induction chemo-
therapy, and what agents are you using nowadays?
Dr Huang. In terms of systemic therapy, we have traditionally
been treating TCs with the same regimens with which we have
treated thymomas in the past. The most commonly used regimens
at our institution have been cisplatin, doxorubicin, and cyclophos-
phamide or cisplatin, and etoposide.1,2 We have been using those
for thymomas and TCs. However, recently, some of our oncologists
have started to approach TCs as a different disease. Because they
seem to be predominantly squamous in histology, we have been ap-
proaching some of these patients with a regimen, such as cisplatin
and docetaxel, more like non–small cell lung cancer.
Several reports now have shown that there is a high proportion of
thymic tumors that overexpress epidermal growth factor receptor,3
raising the possibility of using targeted therapies for these thymic
tumors, and this is an area of active investigation.
Dr Handy. Finally, in light of this report and your publication
last year of use of extended resection in stage IVA thymomas,
how is Sloan–Kettering presently caring for these patients with thy-
moma? Who is receiving chemotherapy and radiation therapy, and
what about reresection, because these are local recurrences? Nice
job on the presentation.
Dr Huang. In general, for the patients with early-stage dis-
ease that is smaller and well encapsulated, most will proceed
straight to surgical intervention. The more challenging patients
that we face are the patients with higher-stage, locally advanced
disease, which present to us with clinically stage III or IVA tu-
mors. These patients will typically need a biopsy to demonstrate
their pathology and then proceed to induction therapy with one
of the regimens that I mentioned before with the goal of treating
to maximum response, usually about 4 cycles of treatment. At
that point, they proceed to surgical resection if they are medi-
cally operable, where the goal is a total thymectomy with en-
bloc resection as necessary. In some cases this might lead to
extended resections, including extrapleural pneumonectomy, if
necessary, in cases of extensive confluent disease, as recently re-
ported by our group and others.4,5 After resection, every patient
with an incomplete resection will receive radiation therapy post-
operatively. Patients with stage III and IVA tumors will usually
receive mediastinal radiation after complete resections. For those
patients who have undergone extrapleural pneumonectomy, these
patients have received hemithoracic radiation to the chest cavity
akin to our approach to pleural mesothelioma.6
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